DrugDashboards

Lopinavir and Ritonavir

Lopinavir and Ritonavir · LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1 · Tablet, Film Coated · AbbVie Deutschland GmbH & Co Kg

NDC 12613-3008-09 · 27000 TABLET, FILM COATED in 1 CARTON · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00074-3008-60) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$4.20per unit
middle half $4.20$4.20 · 2 plans · Apr 1, 2026
Est. net of rebates
≈ $4.20
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
0%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 100%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 8 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for lopinavir and ritonavir (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

  • Planned discontinuation Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-0522-60)Jul 24, 2026
  • Planned discontinuation Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60)Jul 24, 2026
  • Planned discontinuation Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12)Jul 24, 2026
  • Planned discontinuation Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-6799-22)Jul 24, 2026

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Lopinavir and Ritonavir (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
AbbVie Deutschland GmbH & Co KgLOPINAVIR 100 mg/1; RITONAVIR 25 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LOPINAVIR 200 mg/1; RITONAVIR 50 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1Jul 15, 2026Sep 2, 2026
Laurus Labs LimitedLOPINAVIR 200 mg/1; RITONAVIR 50 mg/1Jul 15, 2026Sep 2, 2026
Laurus Labs LimitedLOPINAVIR 100 mg/1; RITONAVIR 25 mg/1Jul 15, 2026Sep 2, 2026
Macleods Pharmaceuticals LimitedLOPINAVIR 200 mg/1; RITONAVIR 50 mg/1Jul 15, 2026Sep 2, 2026
Macleods Pharmaceuticals LimitedLOPINAVIR 100 mg/1; RITONAVIR 25 mg/1Jul 15, 2026Sep 2, 2026
AbbVie Deutschland GmbH & Co KgLOPINAVIR 200 mg/1; RITONAVIR 50 mg/1Jul 15, 2026Aug 31, 2026
AbbVie Inc.LOPINAVIR 200 mg/1; RITONAVIR 50 mg/1Jul 15, 2026Aug 29, 2026
AbbVie Inc.LOPINAVIR 100 mg/1; RITONAVIR 25 mg/1Jul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Lopinavir and Ritonavir — NDC 12613-3008-09," retrieved September 3, 2026, https://drugdashboards.com/drug/12613300809.

Free to cite with attribution — see how the data is put together.